Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups
New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure
In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients
The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care
Login to comment